3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDLcholesterol raising agents

Details for Australian Patent Application No. 2009231376 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Roever, Stephan; Hebeisen, Paul; Panousis, Constantinos G.; Wright, Matthew

Agent Spruson & Ferguson

Pub. Number AU-A-2009231376

PCT Pub. Number WO2009/121741

Priority 08153802.7 31.03.08 EP

Filing date 23 March 2009

Wipo publication date 8 October 2009

International Classifications

C07D 241/28 (2006.01) Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

A61K 31/4965 (2006.01) - Non-condensed pyrazines

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

30 September 2010 PCT application entered the National Phase

  PCT publication WO2009/121741 Priority application(s): WO2009/121741

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009231394-Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders

2009231375-2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents